AlphaRX is an emerging drug delivery company engaged in the development and market of therapeutic products using proprietary drug delivery technologies.
AlphaRX will has commenced Phase II human trials its topical arthritis product - IndaFlex - to fill the void left by Vioxx and Celebrex.
AlphaRx`s primary competence is in the development of novel drug formulations for compounds that are poorly soluble in water or have yet to be administrable to the human body with an acceptable delivery method.
The Company has one U.S. patent issued, three U.S. patents pending and several foreign patents pending for its drug delivery technologies.
The Technology
The insolubility of drugs presents a major problem for the pharmaceutical industry, affecting approximately one third of all drugs listed in the United States Pharmacopoeia. AlphaRx`s proprietary BCD (Bioadhesive Colloidal Dispersion) drug delivery technology dramatically increases the bioavailability of water-insoluble compounds delivered orally or transdermally.
